These innovations may transform metabolic disease treatment over the next decade
The tricky part is that early warning signs can look a lot like typical GLP-1 side effects, so it's easy to write off symptoms that actually deserve attention
Beyond our demonstration of the effects of GLP-1(2836) on IRI and a role for sAC in its biology, there is a small emerging body of evidence supporting a role for GLP-1(2836) in preventing obesity, insulin resistance, diabetes mellitus, and hepatic steatosis and gluconeogenesis in mice (11, 24, 27, 41, 42)
These phase 3 trials are designed to confirm how effective retatrutide is for long-term weight loss and how it may impact other areas tied to weight, like blood sugar, sleep quality in people with sleep apnea, and knee pain linked to osteoarthritis
So how do the medications work
[7] It is important to note that glucagon receptor agonism can also increase hepatic glucose output